Epigenomics AG Statistics
Total Valuation
Epigenomics AG has a market cap or net worth of EUR 780,485. The enterprise value is 11.40 million.
Market Cap | 780,485 |
Enterprise Value | 11.40M |
Important Dates
The last earnings date was Wednesday, July 30, 2025.
Earnings Date | Jul 30, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Epigenomics AG has 876,949 shares outstanding. The number of shares has increased by 0.21% in one year.
Current Share Class | 876,949 |
Shares Outstanding | 876,949 |
Shares Change (YoY) | +0.21% |
Shares Change (QoQ) | -0.20% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | 0.00% |
Float | 622,084 |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 195.12 |
PB Ratio | n/a |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -4.13 |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 21.94
Current Ratio | 21.94 |
Quick Ratio | 21.22 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | -3.80% |
Return on Invested Capital (ROIC) | -6.28% |
Return on Capital Employed (ROCE) | -6.14% |
Revenue Per Employee | 1,333 |
Profits Per Employee | -920,000 |
Employee Count | 2 |
Asset Turnover | 0.00 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +58.93% in the last 52 weeks. The beta is 0.86, so Epigenomics AG's price volatility has been lower than the market average.
Beta (5Y) | 0.86 |
52-Week Price Change | +58.93% |
50-Day Moving Average | 0.83 |
200-Day Moving Average | 1.03 |
Relative Strength Index (RSI) | 53.01 |
Average Volume (20 Days) | 95 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Epigenomics AG had revenue of EUR 4,000 and -2.76 million in losses. Loss per share was -3.15.
Revenue | 4,000 |
Gross Profit | 4,000 |
Operating Income | -726,000 |
Pretax Income | -2.76M |
Net Income | -2.76M |
EBITDA | -1.38M |
EBIT | -726,000 |
Loss Per Share | -3.15 |
Balance Sheet
The company has 764,000 in cash and 11.38 million in debt, giving a net cash position of -10.62 million or -12.11 per share.
Cash & Cash Equivalents | 764,000 |
Total Debt | 11.38M |
Net Cash | -10.62M |
Net Cash Per Share | -12.11 |
Equity (Book Value) | n/a |
Book Value Per Share | n/a |
Working Capital | 754,000 |
Cash Flow
Operating Cash Flow | n/a |
Capital Expenditures | n/a |
Free Cash Flow | n/a |
FCF Per Share | n/a |
Margins
Gross Margin | 100.00% |
Operating Margin | -18,150.00% |
Pretax Margin | -69,000.00% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Epigenomics AG does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -0.21% |
Shareholder Yield | n/a |
Earnings Yield | -353.63% |
FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
The last stock split was on December 8, 2023. It was a reverse split with a ratio of 0.2.
Last Split Date | Dec 8, 2023 |
Split Type | Reverse |
Split Ratio | 0.2 |
Scores
Epigenomics AG has an Altman Z-Score of -10.59 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -10.59 |
Piotroski F-Score | 2 |